Characterization of bone resorbing activity in gingival crevicular fluid from patients with periodontitis.
BACKGROUND
In attempts to elucidate factors stimulating bone resorption in patients with different inflammatory diseases in the vicinity of the skeleton, e.g., peridontal disease and rheumatoid arthritis, we are investigating the presence of bone-resorbing activity in a variety of inflammatory exudates. The aim of the present study was to characterize the bone-resorbing activity present in patients with periodontitis.


METHODS
Bone-resorbing activity was assessed in gingival crevicular fluids (GCFs) collected from patients with periodontitis and from patients with no signs of gingivitis. Bone-resorbing activity was evaluated by analyzing the capacity of GCFs to stimulate the release of minerals and the breakdown of bone matrix proteins in cultured neonatal mouse calvariae. The concentrations of IL-1alpha, IL-1beta and PGE2 were determined with ELISA and RIA techniques, respectively.


RESULTS
GCF eluates from 24 different healthy sites caused a 1.23+/-0.05 fold stimulation of 45Ca release, whereas GCF eluates from 45 different diseased (periodontitis) sites caused a 2.46+/-0.10 fold stimulation. The effect on 45Ca release was time- and concentration-dependent, inhibited by 3 different osteoclast inhibitors and associated with enhanced release of 3H from [3H]-proline-labelled bones. The activity in GCF causing enhanced 45Ca release was unaffected, or in some samples partially reduced, by ultrafiltration using a filter with a molecular weight cut-off of 3000 Daltons. The bone-resorbing activity was temperature sensitive (+90degrees C, 10 min). The concentrations of prostaglandin E2 (PGE2) in the diluted GCF eluates, used in the bone resorption bioassay, were too low to be responsible for the release of 45Ca. Antisera specifically neutralizing human IL-1a inhibited the stimulatory effect of GCF pooled from several diseased sites. The specific, recombinant human IL-1 receptor antagonist completely inhibited the effect of pooled GCFs. GCF eluates from diseased sites contained human IL-1alpha and IL-1beta at concentrations of 1838+/-294 pg/ml and 512+/-91 pg/ml, respectively.


CONCLUSIONS
These data show that GCF contains activity(ies) stimulating osteoclastic bone resorption in vitro. The factor primarily responsible for this activity seems to be IL-1alpha, but IL-1alpha is not the sole activator of bone resorption in GCF.
Rasmussen
L
L
Department of Oral Cell Biology, University of Umeå, Sweden.
Hänström
L
L
Lerner
U H
UH
D000328:Adult; D000368:Aged; D016301:Alveolar Bone Loss / Q000209:etiology; D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D001681:Biological Assay; D001862:Bone Resorption / Q000209:etiology* / Q000378:metabolism; D002118:Calcium / Q000378:metabolism; D016022:Case-Control Studies; D046508:Culture Techniques; D015232:Dinoprostone / Q000032:analysis / Q000378:metabolism*; D005260:Female; D005374:Filtration; D005883:Gingival Crevicular Fluid / Q000737:chemistry* / Q000378:metabolism; D006801:Humans; D007375:Interleukin-1 / Q000032:analysis / Q000378:metabolism*; D008297:Male; D051379:Mice; D008875:Middle Aged; D010010:Osteoclasts / Q000187:drug effects; D010518:Periodontitis / Q000150:complications* / Q000378:metabolism*; D011112:Polymyxin B / Q000494:pharmacology; D017472:Receptors, Interleukin-1 / Q000037:antagonists & inhibitors; D012886:Skull; D013696:Temperature
D000900:Anti-Bacterial Agents; D007375:Interleukin-1; D017472:Receptors, Interleukin-1; D011112:Polymyxin B; D015232:Dinoprostone; D002118:Calcium